AllAnalyst Report
logoArgusSeptember 14, 2020

Charles River Laboratories International, Inc.: Reaffirming BUY rating and raising target to $235

Current Price
Price Target
Earnings Estimate

Charles River Laboratories is a full-service, early-stage contract research organization. It supports the drug discovery efforts of the biotech industry from target identification through nonclinical development. During the nonclinical stage, a drug candidate is tested in vitro (typically on a cellular or subcellular level in a test tube) and in vivo (in animal research models) to support human clinical trials. CRL provides services in basic research, drug discovery, safety and efficacy assessment, clinical support, and manufacturing for a wide range of pharmaceutical and biotech customers. The company is headquartered in Wilmington, Massachusetts and has facilities in the U.S. and overseas.

Subscribe to Yahoo Finance Plus Essential for full access
Exclusive reports, detailed company profiles, and best-in-class trade insights to take your portfolio to the next level
Try it Free

Analyst Profile

David H. Toung

Senior Analyst: Medical Devices & Healthcare Services
David covers the Pharmaceutical, Medical Devices, and Healthcare services sectors for Argus. He has more than two decades of experience in the financial analysis industry, having worked for McDonald & Co., JPMorgan Chase and Standard & Poor's, among others. His commentary has appeared on CNBC and in The New York Times. Prior to his financial career, David was a private practice attorney in New Jersey, and served as a Judicial Clerk for an Appellate Division judge in the New Jersey Superior Court. David has a law degree from Rutgers University, where he was a member of the Law Review. He has a B.A. degree in Government from Cornell University. He has passed Level II of the Chartered Financial Analyst examination.